Tumor Eradication Article Published by Cance...( Preclinical results make compellin...),Health

Preclinical results make compelling case for clinical testing in human

cancer patients

SAN DIEGO, Nov. 12 /PRNewswire/ -- In its Oct. 15 issue, Cancer Research published a peer-reviewed article from Genelux Corporation describing successful eradication of human breast cancer tumors in animals using GL-ONC1, a novel oncolytic virus developed by Genelux scientists. These promising results make a compelling case for the use of GL-ONC1 in human cancer patients. Clinical trials are scheduled to begin in the near future.

"We believe this research represents a significant advance in tumor therapy and diagnosis," said President and CEO Aladar A. Szalay, PhD, an internationally-recognized scientist who founded Genelux Corporation in 2001.

The article, titled "Eradication of Solid Human Tumors in Nude Mice with an Intravenously Injected Light-Emitting Oncolytic Vaccinia Virus," documents animal studies that have resulted in complete eradication of human breast tumors without any observed toxicity using a single intravenous injection of GL-ONC1. In the studies, GL-ONC1 located and replicated selectively within tumors, leading to successful tumor destruction. Scientists were able to monitor tumor regression and elimination in real time using a light-emitting fusion protein encoded in the virus.

GL-ONC1 also stimulated the body's own natural defenses to fight the cancer. After administration, tumor-specific viral colonization enables the immune system to recognize tumors as foreign elements and activate defense mechanisms to fight them. These increased innate and adaptive immune responses further contribute to the regression and eventual eradication of the tumor.

This research was conducted in collaboration with scientists at the National Institutes of Health, Department of Transfusion Medicine and Center for Information Technology, in Bethesda, Maryland; and the Virchow Center for Experimental Biomedicine at t
'/>"/>